Two brands of potassium chloride extended-release capsules are being recalled due to the potential risk of not dissolving, which could lead to cardiac arrest. The first recall is from Glenmark Laboratories, who have recalled 114 batches of their 750 mg capsules. The failure of these capsules to dissolve may cause high potassium levels (hyperkalemia), which can result in irregular heartbeat that could potentially lead to cardiac arrest. This is particularly concerning for patients with underlying conditions such as hypertension, heart failure, or renal dysfunction, as they may be more susceptible to the effects of hyperkalemia.
Similarly, American Health Packaging has issued a recall of 21 batches of the same capsules, which were manufactured by Glenmark but distributed by BluePoint Laboratories. These drugs are used for the treatment of patients with low potassium (hypokalemia) and are packaged in bottles of 100-count and 500-count capsules.
The recalled potassium chloride extended-release capsules were distributed nationwide to wholesale, distributor, and retail outlets. Consumers who have these capsules should consult with their physician or health care provider before stopping their use. Consumers should also contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Mark Huffman, a consumer news reporter for ConsumerAffairs since 2004, is the author of this article. He covers real estate, gas prices, and the economy, and has reported extensively on negative-option sales. Prior to his work at ConsumerAffairs, Huffman was an Associated Press reporter and editor in Washington, D.C., a correspondent for Westwood One Radio Networks and Marketwatch.
